Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations

BACKGROUND: Relapsed and refractory acute myeloid leukemia (RR-AML) still poses major treatment concerns. Current treatments include high doses of cytarabine or fludarabine in combination with cytarabine and G-CSF (FLAG), but provide mixed results. Low-dose decitabine, a hypomethylating drug, in com...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Limin, Zhang, Xiaoqian, Yu, Hongjuan, Zhang, Mingwen, Xu, Mengyuan, Liu, Jie, Fu, Yueyue, Meng, Hongbin, Lyu, Chengfang, Li, Xiaoxia, Zhou, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190628/
https://www.ncbi.nlm.nih.gov/pubmed/30349319
http://dx.doi.org/10.2147/OTT.S161919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190628/
https://www.ncbi.nlm.nih.gov/pubmed/30349319
http://dx.doi.org/10.2147/OTT.S161919

Ejemplares similares